keyword
MENU ▼
Read by QxMD icon Read
search

Perioperative chemotherapy and gastric cancer

keyword
https://www.readbyqxmd.com/read/28513823/adjuvant-radiotherapy-improves-overall-survival-in-patients-with-resected-gastric-adenocarcinoma-a-national-cancer-data-base-analysis
#1
Priscilla K Stumpf, Arya Amini, Bernard L Jones, Matthew Koshy, David J Sher, Christopher H Lieu, Tracey E Schefter, Karyn A Goodman, Chad G Rusthoven
BACKGROUND: For patients with resectable gastric adenocarcinoma, perioperative chemotherapy and adjuvant chemoradiotherapy (CRT) are considered standard options. In the current study, the authors used the National Cancer Data Base to compare overall survival (OS) between these regimens. METHODS: Patients who underwent gastrectomy for nonmetastatic gastric adenocarcinoma from 2004 through 2012 were divided into those treated with perioperative chemotherapy without RT versus those treated with adjuvant CRT...
May 17, 2017: Cancer
https://www.readbyqxmd.com/read/28501086/management-of-locally-advanced-gastroesophageal-cancer-still-a-multidisciplinary-global-challenge
#2
REVIEW
Salah-Eddin Al-Batran, Sylvie Lorenzen
The outcome of patients with locally advanced, resectable gastric cancer, or adenocarcinoma of the gastroesophageal junction is poor. In clinical trials, multimodality therapy, such as perioperative chemotherapy, preoperative or postoperative chemoradiation, or adjuvant chemotherapy led to significant increments in survival. Therefore, experts agree that patients with stage II or III disease should be offered a multidisciplinary treatment approach. However, patients are treated somewhat differently in the different regions of the world and survival rates remain far from being satisfactory...
June 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/28498235/hospital-minimally-invasive-surgery-utilization-for-gastrointestinal-cancer
#3
Meredith C Mason, Hop S Tran Cao, Samir S Awad, Farhood Farjah, George J Chang, Nader N Massarweh
OBJECTIVE: The aim of the study was to evaluate the impact of receiving care at high minimally invasive surgery (MIS)-utilizing hospitals BACKGROUND:: MIS techniques are used across surgical specialties. The extent of MIS utilization for gastrointestinal (GI) cancer resection and impact of receiving care at high utilizing hospitals is unclear. METHODS: This is a retrospective cohort study of 137,581 surgically resected esophageal, gastric, pancreatic, hepatobiliary, colon, and rectal cancer patients within the National Cancer Data Base (2010-2013)...
May 11, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28462649/postoperative-survival-following-perioperative-magic-versus-neoadjuvant-oe02-type-chemotherapy-in-oesophageal-adenocarcinoma
#4
A M Reece-Smith, J H Saunders, I N Soomro, C R Bowman, J P Duffy, P V Kaye, N T Welch, S Madhusudan, S L Parsons
The optimal management of resectable oesophageal adenocarcinoma is controversial, with many centres using neoadjuvant chemotherapy following the Medical Research Council (MRC) oesophageal working group (OE02) trial and the MRC Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. The more intensive MAGIC regimen is used primarily in gastric cancer but some also use it for oesophageal cancer. A database of cancer resections (2001-2013) provided information on survival of patients following either OE02 or MAGIC-type treatment...
May 2017: Annals of the Royal College of Surgeons of England
https://www.readbyqxmd.com/read/28386965/perioperative-chemotherapy-versus-postoperative-chemoradiotherapy-in-patients-with-resectable-gastric-gastroesophageal-junction-adenocarcinomas-a-survival-analysis-of-5058-patients
#5
Timothy L Fitzgerald, Jimmy T Efird, Nelly Bellamy, Suzanne M Russo, Charulata Jindal, Catalina Mosquera, Elizabeth G Holliday, Tithi Biswas
BACKGROUND: Both perioperative chemotherapy (PECT) and postoperative chemoradiotherapy (POCRT) have a significant survival advantage over surgery alone for the treatment of patients with gastric cancer. However, to the best of our knowledge, these regimens have not been compared in a randomized clinical trial. The purpose of the current observational study was to compare overall survival among patients receiving PECT versus POCRT for the treatment of gastric/gastroesophageal junction (GEJ) adenocarcinomas...
April 6, 2017: Cancer
https://www.readbyqxmd.com/read/28337660/topgear-a-randomized-phase-iii-trial-of-perioperative-ecf-chemotherapy-with-or-without-preoperative-chemoradiation-for-resectable-gastric-cancer-interim-results-from-an-international-intergroup-trial-of-the-agitg-trog-eortc-and-cctg
#6
Trevor Leong, B Mark Smithers, Karin Haustermans, Michael Michael, Val Gebski, Danielle Miller, John Zalcberg, Alex Boussioutas, Michael Findlay, Rachel L O'Connell, Jaclyn Verghis, David Willis, Tomas Kron, Melissa Crain, William K Murray, Florian Lordick, Carol Swallow, Gail Darling, John Simes, Rebecca Wong
BACKGROUND: Postoperative chemoradiation and perioperative chemotherapy using epirubicin/cisplatin/5-fluorouracil (ECF) represent two standards of care for resectable gastric cancer. In the TOPGEAR (Trial Of Preoperative therapy for Gastric and Esophagogastric junction AdenocaRcinoma) trial, we hypothesized that adding preoperative chemoradiation to perioperative ECF will improve survival; however, the safety and feasibility of preoperative chemoradiation have yet to be determined. METHODS: TOPGEAR is an international phase III trial in which patients with adenocarcinoma of the stomach were randomized to perioperative ECF alone or with preoperative chemoradiation...
March 23, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28337360/perioperative-epirubicin-oxaliplatin-and-capecitabine-chemotherapy-in-locally-advanced-gastric-cancer-safety-and-feasibility-in-an-interim-survival-analysis
#7
Vikas Ostwal, Arvind Sahu, Anant Ramaswamy, Bhawna Sirohi, Subhadeep Bose, Vikas Talreja, Mahesh Goel, Shraddha Patkar, Ashwin Desouza, Shailesh V Shrikhande
PURPOSE: Perioperative chemotherapy improves survival outcomes in locally advanced (LA) gastric cancer. MATERIALS AND METHODS: We retrospectively analyzed patients with LA gastric cancer who were offered perioperative chemotherapy consisting of epirubicin, oxaliplatin, and capecitabine (EOX) from May 2013 to December 2015 at Tata Memorial Hospital in Mumbai. RESULTS: Among the 268 consecutive patients in our study, 260 patients (97.0%) completed neoadjuvant chemotherapy, 200 patients (74...
March 2017: Journal of Gastric Cancer
https://www.readbyqxmd.com/read/28336807/pmp22-regulates-self-renewal-and-chemoresistance-of-gastric-cancer-cells
#8
Wangyu Cai, Gang Chen, Qicong Luo, Jun Liu, Xiaofeng Guo, Tian Zhang, Fei Ma, Liang Yuan, Boan Li, Jianchun Cai
Cancer stem cells (CSCs) possess self-renewal and chemoresistance activities. However, the manner in which these features are maintained remains obscure. We sought to identify cell surface protein(s) that mark self-renewing and chemoresistant gastric cancer cells using the Explorer Antibody Microarray. We identified PMP22, a target gene of the Wnt/β-catenin pathway, as the most upregulated cell surface protein in gastric cancer xenografts exposed to cisplatin (DDP). PMP22 expression was markedly upregulated in tumorspheric cells and declined with differentiation...
March 23, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28276825/perioperative-chemotherapy-for-resectable-gastric-cancer-what-is-the-evidence
#9
Erling A Bringeland, Hans H Wasmuth, Jon E Grønbech
The UK MAGIC trial published in 2006 was the first RCT to identify improved long-term survival rates using preoperative chemotherapy for resectable gastric or gastroesophageal cancer. Overnight, the treatment regimen impacted European guidelines. However, the majority of patients underwent limited lymph node dissection, and analyses of the rates of curative resection, downsizing and downstaging were not by intention to treat, rightfully raising concerns about their validity. For the subset of true gastric cancers, meta-analyses may even question the claims of improved long-term survival rates by present-day regimens...
June 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28275301/surgery-for-gastric-cancer-patients-of-age-85-and-older-multicenter-survey
#10
Hirotaka Konishi, Daisuke Ichikawa, Hiroshi Itoh, Kenichiro Fukuda, Naoki Kakihara, Manabu Takemura, Kaori Okugawa, Kiyoshi Uchiyama, Masashi Nakata, Hiroshi Nishi, Toshiyuki Kosuga, Shuhei Komatsu, Kazuma Okamoto, Eigo Otsuji
AIM: To investigate the surgical therapies for gastric cancer (GC) patients of age 85 or older in a multicenter survey. METHODS: Therapeutic opportunities for elderly GC patients have expanded in conjunction with extended life expectancy. However, the number of cases encountered in a single institution is usually very small and surgical therapies for elderly GC patients have not yet been standardized completely. In the present study, a total of 134 GC patients of age 85 or older who underwent surgery in 9 related facilities were retrospectively investigated...
February 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28251375/adjuvant-therapy-for-locally-advanced-gastric-cancer
#11
REVIEW
Toru Aoyama, Takaki Yoshikawa
D2 gastrectomy is now the globally accepted surgical standard for locally advanced gastric cancer. However, since 2000, different evidence has emerged regarding the efficacy of adjuvant chemoradiation, perioperative adjuvant chemotherapy, and postoperative chemotherapy for locally advanced gastric cancer. This review summarizes the background, current status, and future perspectives of adjuvant therapy for locally advanced gastric cancer. The Intergroup 0116 study was the first to show the significant overall survival benefits of adjuvant (chemoradiation) therapy for gastric cancer...
March 1, 2017: Surgery Today
https://www.readbyqxmd.com/read/28243814/dna-diagnosis-of-peritoneal-fluid-cytology-test-by-cdo1-promoter-dna-hypermethylation-in-gastric-cancer
#12
Hideki Ushiku, Keishi Yamashita, Akira Ema, Naoko Minatani, Mariko Kikuchi, Ken Kojo, Keigo Yokoi, Toshimichi Tanaka, Nobuyuki Nishizawa, Satoru Ishii, Kei Hosoda, Hiromitsu Moriya, Hiroaki Mieno, Natsuya Katada, Shiro Kikuchi, Hiroshi Katoh, Masahiko Watanabe
BACKGROUND: Minimal residual disease of the peritoneum is challenging for early cancer detection in gastric cancer (GC). Utility of PCR amplification of cancer-derived DNA has been considered feasible due to its molecular stability, however such markers have never been available in GC clinics. We recently discovered cancer-specific methylation of CDO1 gene in GC, and investigated the clinical potential to detect the minimal residual disease. METHODS: One hundred and two GC patients were investigated for peritoneal fluid cytology test (CY), and detection level of the promoter DNA methylation of CDO1 gene was assessed by quantitative methylation specific PCR (Q-MSP) in the sediments (DNA CY)...
February 27, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28241187/mismatch-repair-deficiency-microsatellite-instability-and-survival-an-exploratory-analysis-of-the-medical-research-council-adjuvant-gastric-infusional-chemotherapy-magic-trial
#13
Elizabeth C Smyth, Andrew Wotherspoon, Clare Peckitt, David Gonzalez, Sanna Hulkki-Wilson, Zakaria Eltahir, Matteo Fassan, Massimo Rugge, Nicola Valeri, Alicia Okines, Madeleine Hewish, William Allum, Sally Stenning, Matthew Nankivell, Ruth Langley, David Cunningham
Importance: Mismatch repair (MMR) deficiency (MMRD) and microsatellite instability (MSI) are prognostic for survival in many cancers and for resistance to fluoropyrimidines in early colon cancer. However, the effect of MMRD and MSI in curatively resected gastric cancer treated with perioperative chemotherapy is unknown. Objective: To examine the association among MMRD, MSI, and survival in patients with resectable gastroesophageal cancer randomized to surgery alone or perioperative epirubicin, cisplatin, and fluorouracil chemotherapy in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial...
February 23, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28118758/molecular-classification-of-gastric-cancer
#14
Christoph Röcken
Gastric cancer is among the most common cancers worldwide. Despite declining incidences, the prognosis remains dismal in Western countries and is better in Asian countries with national cancer screening programs. Complete endoscopic or surgical resection of the primary tumor with or without lymphadenectomy offers the only chance of cure in the early stage of the disease. Survival of more locally advanced gastric cancers was improved by the introduction of perioperative, adjuvant and palliative chemotherapy...
March 2017: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/28044374/histopathological-regression-of-gastric-adenocarcinoma-after-neoadjuvant-therapy-a-critical-review
#15
REVIEW
Eduardo Henrique Cunha Neves Filho, Rosane Oliveira de Sant'Ana, Luiz Vianney Saldanha Cidrão Nunes, Adriana Pinheiro Bezerra Pires, Maria do Perpétuo Socorro Saldanha da Cunha
As the perioperative chemotherapy has been widely implemented on the management of gastric cancer patients, heterogeneity of clinical outcomes has been evidenced in parallel to different histopathological regression pattern of gastric cancer cells. Tumor histological response to preoperative therapy has been graded by various systems in order to categorize the amount of regressive changes induced by chemotherapy in relation to residual tumor. In this context, tumor regression grading (TRG) systems might provide important prognostic information as the variety of tumor response may imply on different clinical outcomes with impact in survival rates...
February 2017: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica
https://www.readbyqxmd.com/read/27987041/prevalence-of-deep-venous-thrombosis-detected-by-ultrasonography-before-surgery-in-patients-with-gastric-cancer-a-retrospective-study-of-1140-consecutive-patients
#16
Yutaka Tanizawa, Etsuro Bando, Taiichi Kawamura, Masanori Tokunaga, Rie Makuuchi, Kei Iida, Kazuhide Nanri, Masashi Yoneyama, Masanori Terashima
BACKGROUND: The prevalence of deep venous thrombosis (DVT) in patients with gastric cancer before surgery is unknown. This study aimed to clarify the risk factors for DVT of the lower extremities in patients with gastric cancer before surgery and to evaluate the usefulness of ultrasonographic screening for prevention of postoperative pulmonary thromboembolism (PTE). METHODS: Patients who had undergone lower-extremity venous ultrasonography before surgery for gastric cancer were retrospectively analyzed...
December 16, 2016: Gastric Cancer
https://www.readbyqxmd.com/read/27776843/histopathological-regression-after-neoadjuvant-docetaxel-oxaliplatin-fluorouracil-and-leucovorin-versus-epirubicin-cisplatin-and-fluorouracil-or-capecitabine-in-patients-with-resectable-gastric-or-gastro-oesophageal-junction-adenocarcinoma-flot4-aio-results
#17
Salah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, Hans-Georg Kopp, Georg Martin Haag, Kim Barbara Luley, Johannes Meiler, Nils Homann, Sylvie Lorenzen, Harald Schmalenberg, Stephan Probst, Michael Koenigsmann, Matthias Egger, Nicole Prasnikar, Karel Caca, Jörg Trojan, Uwe M Martens, Andreas Block, Wolfgang Fischbach, Rolf Mahlberg, Michael Clemens, Gerald Illerhaus, Katja Zirlik, Dirk M Behringer, Wolff Schmiegel, Michael Pohl, Michael Heike, Ulrich Ronellenfitsch, Martin Schuler, Wolf O Bechstein, Alfred Königsrainer, Timo Gaiser, Peter Schirmacher, Wael Hozaeel, Alexander Reichart, Thorsten O Goetze, Mark Sievert, Elke Jäger, Stefan Mönig, Andrea Tannapfel
BACKGROUND: Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma, but has not yet been evaluated in the context of resectable patients. Here we report findings from the phase 2 part of the phase 2/3 FLOT4 trial, which compared histopathological regression in patients treated with a docetaxel-based triplet chemotherapy versus an anthracycline-based triplet chemotherapy before surgical resection. METHODS: In this randomised, open-label, phase 2/3 study, eligible participants were recruited from 28 German oncology centres...
December 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27697984/multimodality-therapy-of-localized-gastric-adenocarcinoma
#18
REVIEW
Brian Badgwell
Surgical resection is the primary method of obtaining a potential cure for patients with gastric adenocarcinoma. However, chemotherapy or chemoradiotherapy offer significant improvement in survival over surgery alone. Much of the difficulty in deciding the optimal treatment strategy is choosing between perioperative chemotherapy or adjuvant chemoradiotherapy. Adding to the complexity is the potential for incorporating treatment strategies based on clinical trials performed in Asia. There is likely a difference in tumor biology between Eastern and Western patients with gastric adenocarcinoma, in addition to the clear differences in screening, pathologic assessment, and surgical technique...
October 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27644906/gastric-cancer-adjuvant-therapy
#19
REVIEW
Florian Lordick, Masanori Terashima
From a global perspective, gastric cancer is one of the most common and lethal forms of cancer. The incidence of gastric cancer is very high in East Asia and varies considerably in countries of the Western hemisphere. Even after curative resection, the relapse rates are high in stages II and III. Therefore, adjuvant treatment with chemotherapy has been studied with positive results, especially in East Asian populations. In the Western World, where many locally advanced and borderline resectable gastric cancers are diagnosed, perioperative chemotherapy has become a standard of care...
August 2016: Best Practice & Research. Clinical Gastroenterology
https://www.readbyqxmd.com/read/27574566/-magic-of-our-gastric-cancer-results-on-perioperative-chemotherapy
#20
Carlos León-Espinoza, Fernando López-Mozos, Roberto Marti-Obiol, Marina Garces-Albir, Joaquin Ortega-Serrano
AIM: To determine reproducibility of perioperative chemotherapy for gastric cancer (GC) on our settings by identifying patient's overall survival and comparing them to larger studies. METHODS: Retrospective analysis of our series, where we present our eleven-year's experience on GC managed according to perioperative approach of three preoperative chemotherapy cycles followed by surgery and finally three postoperative chemotherapy cycles. Chemotherapic scheme used was Xelox (Oxaliplatin and Capecitabine)...
August 15, 2016: World Journal of Gastrointestinal Pathophysiology
keyword
keyword
110857
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"